How to Cite
Abstract
Staging is the most important step in the management of patients with cancer; it directly correlates with prognosis and the choice of specialized treatment, while facilitating the exchange of information between medical experts. A staging system must have three main characteristics: it must be effective, reliable and practical. The current staging system (classification) for endometrial cancer was developed in 2009, is highly reproducible and does not require excessive diagnostic testing. At the same time, there are many 'grey areas' in the classification, which make it difficult to choose the right treatment for patients who fall into them. The most striking example is the need for lymph node dissection in clinical stage I endometrial cancer, where the decision to perform it is left to the discretion of the treating physician in the case of intermediate risk. To address this problem and to try to individualize treatment and stratify the risk of recurrence, molecular classification has become widespread in recent years. In 2023, the International Federation of Gynecology and Obstetrics proposed a new staging system for endometrial cancer. This review focuses on historical aspects of the development of the concept of systemic assessment of endometrial cancer and allows us to better appreciate recent advances in understanding the biology of endometrial tumors.
References
Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022; (илл.): 239. [Ed. by Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2022 (morbidity and mortality). Moscow: P.A. Herzen Moscow State Medical Research Institute - branch of the Federal State Budgetary Institution «NMRC of Radiology» of the Ministry of Health of Russia. 2022; (ill.): 252. (In Rus)].
Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022: 239. [Ed. by Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2021 (morbidity and mortality). State of oncological care for the population of Russia in 2021. Moscow: P.A. Herzen Moscow State Medical Research Institute - branch of the Federal State Budgetary Institution «NMRC of Radiology» of the Ministry of Health of Russia. 2022: 239. (In Rus)].
Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2021; 71(3): 209-249.-DOI: https://doi.org/10.3322/caac.21660.
Arnold M., Pandeya N., Byrnes G., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015; 16(1): 36-46.-DOI: https://doi.org/10.1016/S1470-2045(14)71123-4.
Нечушкина В.М., Коломиец Л.А., Кравец О.А., et al. Рак тела матки и саркомы матки. Злокачественные опухоли. 2023; 13(3s2-1): 263-279.-DOI: https://doi.org/10.18027/2224-5057-2023-13-3s2-1-263-279. [Nechushkina V.M., Kolomiets L.A., Kravets O.A., et al. Cancer of the corporis uteri and sarcoma of the uterus. Malignant Tumors. 2023; 13(3s2-1): 263-279.-DOI: https://doi.org/10.18027/2224-5057-2023-13-3s2-1-263-279. (In Rus)].
Talhouk A., McConechy M.K., Leung S., et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5): 802-813.-DOI: https://doi.org/10.1002/cncr.30496.
Cancer Genome Atlas Research Network; Kandoth C., Schultz N., et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67-73.-DOI: https://doi.org/10.1038/nature12113.
Guan J., Xie L., Luo X., et al. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. J Gynecol Oncol. 2019; 30(1): e13.-DOI: https://doi.org/10.3802/jgo.2019.30.e13.
Talhouk A., McAlpine J.N. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016; 3: 14.-DOI: https://doi.org/10.1186/s40661-016-0035-4.
Bell D.W., Ellenson L.H. Molecular genetics of endometrial carcinoma. Annu Rev Pathol. 2019; 14: 339-367.-DOI: https://doi.org/10.1146/annurev-pathol-020117043609.
Zheng W. Molecular classification of endometrial cancer and the 2023 FIGO staging: exploring the challenges and opportunities for pathologists. Cancers (Basel). 2023; 15(16): 4101.-DOI: https://doi.org/10.3390/cancers15164101.
Berek J.S., Matias-Guiu X., Creutzberg C., et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023; 162(2): 383-394.-DOI: https://doi.org/10.1002/ijgo.14923.
Mikuta J.J. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer. 1993; 71(4 Suppl): 1460-3.-DOI: https://doi.org/10.1002/cncr.2820710409.
Lewis B.V., Stallworthy J.A., Cowdell R. Adenocarcinoma of the body of the uterus. J Obstet Gynaecol Br Commonw. 1970; 77(4): 343-8.-DOI: https://doi.org/10.1111/j.1471-0528.1970.tb03530.x.
Schwartz A.E., Brunschwig A. Radical panhysterectomy and pelvic node excision for carcinoma of the corpus uteri. Surg Gynecol Obstet. 1957; 105(6): 675-80.
Roden A.T. The treatment of carcinoma of the body of the uterus. Proc R Soc Med. 1964; 57(6): 467-78.
Rickford R.B.K. Involvement of pelvic lymph nodes in carcinoma. Amer J Obstet Gynecol. 1965; 91: 1060-1065.
Lees D.H. An evaluation of treatment in carcinoma of the body of the uterus. J Obstet Gynaecol Brit Commonw. 1969; 76: 615-623.
Creasman W.T., Boronow R.C., Morrow C.P., et al. Adenocarcinoma of the endometrium: its metastatic lymph node potential. A preliminary report. Gynecol Oncol. 1976; 4(3): 239-43.-DOI: https://doi.org/10.1016/0090-8258(76)90028-7.
Boronow R.C., Morrow C.P., Creasman W.T., et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984; 63(6): 825-32.
DiSaia P.J., Creasman W.T., Boronow R.C., Blessing J.A. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985; 151(8): 1009-15.-DOI: https://doi.org/10.5555/uri:pii:0002937885903710.
Creasman W.T., Morrow C.P., Bundy B.N., et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987; 60(8 Suppl): 2035-41.-DOI: https://doi.org/10.1002/1097-0142(19901015)60:8+<2035::aid-cncr2820601515>3.0.co;2-8.
Morrow C.P., Bundy B.N., Kurman R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991; 40(1): 55-65.-DOI: https://doi.org/10.1016/0090-8258(91)90086-K.
Rungruang B., Olawaiye A.B. Comprehensive surgical staging for endometrial cancer. Rev Obstet Gynecol. 2012; 5(1): 28-34.
Boronow R.C. Endometrial cancer and surgical staging: a personal assessment. Philipp J Obstet Gynecol. 1998; 22(3): 71-7.
Abu-Rustum N.R., Zhou Q., Iasonos A., et al. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer. 2011; 21(3): 511-6.-DOI: https://doi.org/10.1097/IGC.0b013e31820cc305.
Creasman W.T., Odicino F., Maisonneuve P., et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1: S105-43.-DOI: https://doi.org/10.1016/S0020-7292(06)60031-3.
McEachron J., Marshall L., Zhou N., et al. Evaluation of survival, recurrence patterns and adjuvant therapy in surgically staged high-grade endometrial cancer with retroperitoneal metastases. Cancers. 2021; 13(9): 2052.-DOI: https://doi.org/10.3390/cancers13092052.
Morice P., Leary A., Creutzberg C., et al. Endometrial cancer. Lancet (London, England). 2016; 387(10023): 1094-1108.-DOI: https://doi.org/10.1016/S0140-6736(15)00130-0.
Höhn A.K., Brambs C.E., Hiller G.G.R., et al. 2020 WHO classification of female genital tumors. Vol 4. 5th ed. IARC Press. 2020.-DOI: https://doi.org/10.1055/a-1545-4279.
McAlpine J.N., Temkin S.M., Mackay H.J. Endometrial cancer: not your grandmother's cancer. Cancer. 2016; 122(18): 2787‐2798.-DOI: https://doi.org/10.1002/cncr.30094.
National Institutes of Health Cancer Facts: Uterine cancer. Surveillance, Epidemiology, and End Results Program.-URL: https://seer.cancer.gov/statfacts/html/corp.html.
Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA: a Cancer Journal for Clinicians. 2023; 73(1): 17-48.-DOI: https://doi.org/10.3322/caac.21763.
Heidinger M., Simonnet E., Koh L. et al. Therapeutic approaches in patients with bone metastasis due to endometrial carcinoma - A systematic review. Journal of Bone Oncology. 2023; 41: 100485.-DOI: https://doi.org/10.1016/j.jbo.2023.100485.
Chan J.K., Wu H., Cheung M.K., et al. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol. 2007; 106: 282-8.-DOI: https://doi.org/10.1016/j.ygyno.2007.05.033.
Straughn J.M. Jr., Huh W.K., Kelly F.J., et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol. 2002; 84: 194-200.-DOI: https://doi.org/10.1006/gyno.2001.6494.
Wright J.D., Fiorelli J., Schiff P.B., et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer. 2009; 115: 1276-85.-DOI: https://doi.org/10.1002/cncr.24160.
Lewin S.N., Herzog T.J., Barrena Medel N.I., et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol. 2010; 116(5): 1141-9.-DOI: https://doi.org/10.1097/AOG.0b013e3181f39849.
Reisinger S.A., Staros E.B., Mohiuddin M. Survival and failure analysis in stage II endometrial cancer using the revised 1988 figo staging system. Int J Radiat Oncol Biol Phys. 1991; 21(4): 1027-32.-DOI: https://doi.org/10.1016/0360-3016(91)90745-p.
Sartori E., Gadducci A., Landoni F., et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001; 11: 430-7.-DOI: https://doi.org/10.1046/j.1525-1438.2001.01061.x.
Cohn D.E., Woeste E.M., Cacchio S., et al. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol. 2007; 109: 1062-7.15.-DOI: https://doi.org/10.1097/01.AOG.0000260871.87607.25.
Wright J.D., Fiorelli J., Kansler A.L., et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol. 2009; 200: 419.e1-7.-DOI: https://doi.org/10.1016/j.ajog.2008.11.003.
Geller M.A., Ivy J., Dusenbery K.E., et al. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the ‘sandwich’ method for high risk endometrial carcinoma. Gynecol Oncol. 2010; 118: 19-23.-DOI: https://doi.org/10.1016/j.ygyno.2009.11.025.
Secord A.A., Havrilesky L.J., O’Malley D.M., et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol. 2009; 114: 442-7.-DOI: https://doi.org/10.1016/j.ygyno.2009.06.005.
Havrilesky L.J., Cragun J.M., Calingaert B., et al. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol. 2007; 104: 401-5.-DOI: https://doi.org/10.1016/j.ygyno.2006.08.027.
Mariani A., Webb M.J., Keeney G.L., et al. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol. 2002; 86: 38-44.-DOI: https://doi.org/10.1006/gyno.2002.6713.
Tebeu P.M., Popowski G.Y., Verkooijen H.M., et al. Impact of peritoneal cytology on survival of endometrial cancer patients treated with surgery and radiotherapy. Br J Cancer. 2003; 89: 2023-6.-DOI: https://doi.org/10.1038/sj.bjc.6601446.
Mariani A., Dowdy S.C., Podratz K.C. New surgical staging of endometrial cancer: 20 years later. Int J Gynaecol Obstet. 2009; 105(2): 110-1.-DOI: https://doi.org/10.1016/j.ijgo.2009.02.008.
Stelloo E., Nout R.A., Osse E.M., et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016; 22(16): 4215-24.-DOI: https://doi.org/10.1158/1078-0432.CCR-15-2878.
León-Castillo A., de Boer S.M., Powell M.E., et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020; 38(29): 3388-3397.-DOI: https://doi.org/10.1200/JCO.20.00549.
Mitric C., Bernardini M.Q. Endometrial cancer: transitioning from histology to genomics. Curr Oncol. 2022; 29(2): 741-757.-DOI: https://doi.org/10.3390/curroncol29020063.
van Gool I.C., Bosse T., Church D.N. POLE proofreading mutation, immune response and prognosis in endometrial cancer. Oncoimmunology. 2015; 5(3): e1072675.-DOI: https://doi.org/10.1080/2162402X.2015.1072675.
Jamieson A., Thompson E.F., Huvila J., et al. p53abn endometrial cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. Int J Gynecol Cancer. 2021; 3: 1312.-DOI: https://doi.org/10.1136/ijgc-2020-002256.
Drocaş I., Crăiţoiu Ş., Stepan A.E., et al. The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas. Rom J Morphol Embryol. 2022; 63(1): 113-120.-DOI: https://doi.org/10.47162/RJME.63.1.11.
Canlorbe G., Laas E., Bendifallah S., et al. Contribution of immunohistochemical profile in assessing histological grade of endometrial cancer. Anticancer Res. 2013; 33(5): 2191-8.
Porzio R., Cordini C., Rodolfi A.M., et al. Triple negative endometrial cancer: Incidence and prognosis in a monoinstitutional series of 220 patients. Oncol Lett. 2020; 19(3): 2522-2526.-DOI: https://doi.org/10.3892/ol.2020.11329.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024